Fortis Group Advisors LLC Makes New $1.02 Million Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Fortis Group Advisors LLC acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,482 shares of the company's stock, valued at approximately $1,019,000.

A number of other institutional investors have also recently made changes to their positions in the business. Victory Capital Management Inc. grew its stake in Hims & Hers Health by 173.9% during the 1st quarter. Victory Capital Management Inc. now owns 144,006 shares of the company's stock valued at $4,255,000 after purchasing an additional 91,427 shares during the last quarter. Larson Financial Group LLC grew its stake in Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $1,241,000. Sigma Planning Corp grew its stake in Hims & Hers Health by 21.1% during the 1st quarter. Sigma Planning Corp now owns 58,874 shares of the company's stock valued at $1,740,000 after purchasing an additional 10,247 shares during the last quarter. Finally, Signaturefd LLC grew its stake in Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their target price for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Piper Sandler restated a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday. Finally, Truist Financial upped their target price on Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research note on Thursday. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $39.83.

Insider Buying and Selling

In other news, insider Michael Chi sold 17,102 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the transaction, the insider owned 278,654 shares in the company, valued at approximately $16,649,576.50. This represents a 5.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $47.70, for a total value of $552,413.70. Following the completion of the transaction, the chief financial officer owned 54,084 shares in the company, valued at approximately $2,579,806.80. The trade was a 17.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 683,452 shares of company stock worth $36,247,465 in the last quarter. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $0.37 during trading hours on Friday, hitting $50.36. The company's stock had a trading volume of 22,036,786 shares, compared to its average volume of 24,206,590. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The firm has a fifty day moving average of $53.82 and a 200-day moving average of $42.04. The stock has a market cap of $11.27 billion, a price-to-earnings ratio of 72.99, a P/E/G ratio of 1.85 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the prior year, the company earned $0.05 EPS. Hims & Hers Health's revenue was up 110.7% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.